dm+d

Unassigned

New Medicines

Symptomatic uterine fibroids

Information

New molecular entity
Bayer
Bayer

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Feb 21In its latest annual report, Bayer announces that it decided to discontinue development of vilaprisan in November 2020. A comprehensive assessment of the generated preclinical and clinical data is currently being conducted [9].

Category

A small molecule progesterone receptor antagonist
Uterine fibroids (uterine leiomyomas) are the most common non-cancerous tumours in women of childbearing age, occurring in 77% of women. Uterine fibroids are the single most common indication for hysterectomy. They are clinically apparent in up to 25% of women [1].
Symptomatic uterine fibroids
Oral